- Author:
Seon Ho BAK
1
;
Hyun Ho CHOI
;
Jinhee LEE
;
Mi Hee KIM
;
Youn Hee LEE
;
Jin Su KIM
;
Young Seok CHO
Author Information
- Publication Type:Case Report
- Keywords: Crohn disease; Fecal microbiota transplantation; Dysbiosis; Biologic therapy
- MeSH: Biological Therapy; Colitis; Crohn Disease*; Dysbiosis; Fecal Microbiota Transplantation*; Gastrointestinal Microbiome; Humans; Immune System; Inflammation; Inflammatory Bowel Diseases; Lymphoma
- From:Intestinal Research 2017;15(2):244-248
- CountryRepublic of Korea
- Language:English
- Abstract: Approximately one-third of patients with Crohn's disease do not respond to conventional treatments, and some experience significant adverse effects, such as serious infections and lymphoma, and many patients require surgery due to complications. Increasing evidence suggests that specific changes in the composition of gut microbiota, termed as dysbiosis, are a common feature in patients with inflammatory bowel disease (IBD). Dysbiosis can lead to activation of the mucosal immune system, resulting in chronic inflammation and the development of mucosal lesions. Recently, fecal microbiota transplantation, aimed at modifying the composition of gut microbiota to overcome dysbiosis, has become a potential alternative therapeutic option for IBD. Herein, we present a patient with Crohn's colitis in whom biologic therapy failed previously, but clinical remission and endoscopic improvement was achieved after a single fecal microbiota transplantation infusion.